<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057798</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000270753</org_study_id>
    <secondary_id>RPCI-RP-00-01</secondary_id>
    <nct_id>NCT00057798</nct_id>
  </id_info>
  <brief_title>Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery</brief_title>
  <official_title>Molecular And Genetic Changes In Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) Following Neoadjuvant Chemotherapy With Vinorelbine And Gemcitabine - Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Determination of genetic changes in patients with non-small cell lung cancer may&#xD;
      help predict the outcome of treatment. Drugs used in chemotherapy use different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Combining more than one drug, and&#xD;
      giving them before surgery, may shrink the tumor so that it can be removed during surgery.&#xD;
&#xD;
      PURPOSE: Phase II trial to study genetic changes and the effectiveness of combining&#xD;
      vinorelbine with gemcitabine before surgery in treating patients who have stage IB, stage II,&#xD;
      or stage III non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the frequency of expression of epithelial markers CK19, CK20, MUC1, and MUC5&#xD;
           (by reverse transcriptase-polymerase chain reaction) in lymph node tissue and blood&#xD;
           samples of patients with resectable stage IB-III non-small cell lung cancer treated with&#xD;
           neoadjuvant vinorelbine and gemcitabine followed by surgery.&#xD;
&#xD;
        -  Determine the expression of the multidrug resistance-associated protein gene before and&#xD;
           after treatment with this regimen in these patients.&#xD;
&#xD;
        -  Determine the global expression profile of genes (by microarray technology) in tumor&#xD;
           tissue of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the frequency of loss of heterozygosity at several loci on chromosomes 3p, 9p,&#xD;
           and 11p before and after treatment with this regimen in these patients.&#xD;
&#xD;
        -  Determine the percent positivity of cells that stain for MCM2 and CDC6 (prereplicative&#xD;
           complex) by immunohistochemistry before and after treatment with this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the feasibility of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pathological response rates in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the side effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the disease-free and overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the autologous immune response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive vinorelbine IV over 6-10 minutes and gemcitabine IV over 30 minutes&#xD;
      on days 1, 8, 22, and 29 in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with no disease progression by scans or bronchoscopy undergo surgical resection&#xD;
      between days 57-70 (weeks 8-10).&#xD;
&#xD;
      Loss of heterozygosity (LOH) at loci on chromosomes 3p, 9p, and 11p is assessed in blood&#xD;
      specimens, tumor tissue, and noncancerous tissue before and after chemotherapy. Specimens are&#xD;
      also examined for molecular markers of occult metastasis using reverse&#xD;
      transcriptase-polymerase chain reaction. Multidrug resistance-associated protein gene&#xD;
      expression is also determined using microarray technology.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 5 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">21</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine ditartrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>loss of heterozygosity analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell carcinoma of the lung&#xD;
&#xD;
               -  May be confirmed at the initial bronchoscopy and mediastinoscopy&#xD;
&#xD;
               -  Stage IB (T2, N0, M0)&#xD;
&#xD;
               -  Stage IIA (T1, N1, M0)&#xD;
&#xD;
               -  Stage IIB (T2-3, N0-1, M0)&#xD;
&#xD;
               -  Stage IIIA (T1-3, N1-2, M0)&#xD;
&#xD;
               -  stage IIIB (2 lesions in 1 lobe [T4])&#xD;
&#xD;
          -  No N3 lymph nodes (contralateral mediastinal/hilar and supraclavicular/scaline) OR T4&#xD;
             primary tumor (malignant pleural effusion or mediastinal invasion) by clinical staging&#xD;
             criteria (seen on CT or PET scan and proven by mediastinoscopy)&#xD;
&#xD;
          -  No metastatic disease (except N1 or N2 disease) or malignant pleural effusion*&#xD;
             detected on preoperative evaluation&#xD;
&#xD;
               -  No exudative effusions (even if cytologically negative)&#xD;
&#xD;
                    -  Pleural fluid is considered exudative if the following apply:&#xD;
&#xD;
                         -  Ratio of pleural fluid protein to serum protein is greater than 0.5&#xD;
&#xD;
                         -  Ratio of pleural fluid lactic dehydrogenase (LDH) to serum LDH is at&#xD;
                            least 0.6&#xD;
&#xD;
                         -  Pleural fluid LDH is greater than 200 IU/L&#xD;
&#xD;
               -  No multiple areas of fluorodeoxyglucose (FDG) uptake** outside the area of the&#xD;
                  primary tumor in the lung NOTE: *Effusions visible only on CT scan and not large&#xD;
                  enough for safe thoracentesis are allowed&#xD;
&#xD;
        NOTE: **If only 1 area shows an increase in FDG uptake, the area of concern requires&#xD;
        further evaluation (e.g., biopsy) to exclude metastatic disease&#xD;
&#xD;
          -  Bidimensionally measurable or evaluable disease* NOTE: *Lesions apparent on chest CT&#xD;
             scan (e.g., ill-defined masses associated with post obstructive changes and&#xD;
             mediastinal or hilar adenopathy measurable in 1 dimension) are considered evaluable&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST or ALT no greater than 1.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Deemed medically fit for surgical resection&#xD;
&#xD;
          -  No other active malignancy within the past 2 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No psychological, sociological, or geographical condition that would preclude study&#xD;
             compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Concurrent participation in the RPCI vaccine study (postoperative vaccination with&#xD;
             autologous tumor-associated antigen-pulsed dendritic cells) is allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for lung cancer&#xD;
&#xD;
          -  No concurrent participation in another study involving other chemotherapy agents&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for lung cancer&#xD;
&#xD;
          -  No concurrent participation in another study involving radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior surgery for lung cancer&#xD;
&#xD;
          -  More than 3 months since other prior major surgery (e.g., coronary artery bypass&#xD;
             graft)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other prior therapy for lung cancer&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
&#xD;
          -  Concurrent participation in observational studies requiring bloodwork, radiographs,&#xD;
             pulmonary function tests, or quality of life studies is allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nithya Ramnath, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ramnath N, Sommers E, Anderson T, et al.: Neoadjuvant gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2818, 2003.</citation>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <last_update_submitted>March 7, 2011</last_update_submitted>
  <last_update_submitted_qc>March 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Nithya Ramnath, MD</name_title>
    <organization>Roswell Park Cancer Institute</organization>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

